Antibiotics Against Endocarditis – Past, Present and Future (Experimental Data)

Jacqueline, Cédric; Amador, Gilles; Batard, Éric; Mabecque, Virginie Le; Potel, G.; Caillon, Jocelyne

doi:10.5772/26769

Endocarditis 2012

DOI: 10.5772/26769

|View full text |Cite

Antibiotics Against Endocarditis – Past, Present and Future (Experimental Data)

Cédric Jacqueline¹,

Gilles Amador²,

Éric Batard³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2016

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 60 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is a novel ␤-lactam that has a maximum affinity for PBP2a, which confers MRSA resistance via the mecA gene (3,4). In 2010, the U.S. Food and Drug Administration (FDA) approved ceftaroline for use in the treatment of acute bacterial skin and skin structure infections (SSSI) as well as community-acquired pneumonia (CAP) in patients18 years or older (4)(5)(6). Additionally, ceftaroline has bactericidal activity against MRSA, therefore serving as an attractive alternative agent for the treatment of MRSA bacteremia when approved agents are contraindicated or treatment failures have occurred.…”

mentioning

confidence: 99%

Neutropenia Associated with Long-Term Ceftaroline Use

LaVie

Anderson

O’Neal

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

dCeftaroline is a fifth-generation cephalosporin with potent antimicrobial activity against Gram-positive and Gram-negative pathogens. Neutropenia is a rare serious adverse event for the class of cephalosporins; however, we observed several cases of severe neutropenia in our outpatient infectious disease practice believed to be associated with ceftaroline use. The aim of this study was to determine the incidence of neutropenia among patients receiving ceftaroline therapy for more than 7 days. We conducted a retrospective cohort analysis of patients admitted to an 800-bed regional medical center between June 2012 and December 2014 who received ceftaroline for more than 7 days to assess the incidence of developing clinically significant neutropenia. Demographic and patient care data points as well as underlying admitting and chronic diagnoses were retrospectively collected from the medical record. Clinically significant neutropenia was defined as an absolute neutrophil count (ANC) less than 1,500 cells/ mm 3 . Analysis was performed to determine the incidence, severity, and outcome of neutropenia following ceftaroline administration. A total of 39 patients were included in the cohort. The median duration of therapy was 27 days. Seven patients (18%) developed neutropenia while on ceftaroline therapy. Four (10%) of the neutropenic patients had an ANC of <500 cells/mm 3 . The median first neutropenic day was day 17, with the median ANC nadir of 432 cells/mm 3 on day 24. We determined that extended ceftaroline infusion is associated with the development of neutropenia. We recommend obtaining a complete blood count (CBC) with differential at the onset of therapy and weekly thereafter. Should the ANC fall below 2,500 cells/mm 3 , then twice-weekly CBCs should be monitored for the duration of ceftaroline therapy, and therapy should be discontinued if the ANC falls to 1,500 cells/mm 3 or less.

show abstract

mentioning

confidence: 99%

Neutropenia Associated with Long-Term Ceftaroline Use

LaVie

Anderson

O’Neal

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Antibiotics Against Endocarditis – Past, Present and Future (Experimental Data)

Cited by 1 publication

References 60 publications

Neutropenia Associated with Long-Term Ceftaroline Use

Neutropenia Associated with Long-Term Ceftaroline Use

Contact Info

Product

Resources

About